Nasdaq
$90.33▲ 0.08%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $7.84BShares out 86.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
25- 10.9After-hours26.10.10 06:00SCHEDULE 13D/AOwnership#●●●#●●●
Spyre Therapeutics, Inc.
Fairmount Funds Management LLC has filed a SCHEDULE 13D/A regarding its beneficial ownership in Spyre Therapeutics, Inc. This filing serves as an official update to the reporting party's equity holdings in the company.…more
$90.33+0.08%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.7Pre-market26.10.07 21:008-KKey event
Spyre Therapeutics, Inc.
Spyre Therapeutics finalized a public offering of 4,117,648 shares of common stock at a price of $85.00 per share on October 5, 2026. The company expects gross proceeds of approximately $350 million, which will be used to advance clinical trials and R&D programs in gastroenterology, rheumatology, and dermatology. Additionally, the underwriters were granted a 30-day option to purchase up to 617,647 additional shares.…more
$90.33+0.08%vs prev closeView filingShare - 10.6After-hours26.10.07 05:41424B5Offering
Spyre Therapeutics, Inc.
Spyre Therapeutics is offering 4,117,648 shares of its common stock at a public offering price of $85.00 per share, raising approximately $350 million in gross proceeds. The underwriters have a 30-day option to purchase up to an additional 617,647 shares, and the proceeds will be used for research, development, and general corporate purposes.…more
$90.33+0.08%vs prev closeView filingShare
24 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 6d agoOvernight26.10.19 15:54#●●●#●●●
Spyre Therapeutics Demonstrates Efficacy of Antibody Candidates in Colitis Model at UEGW 2026…more
Spyre Therapeutics announced at UEGW 2026 that its anti-α4β7, anti-TL1A, and anti-IL-23 antibody candidates showed efficacy in humanized mouse colitis models. The study further highlighted that combination therapies provided enhanced therapeutic results.…more
$90.33+0.08%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 6d agoClosed26.10.18 22:30
●●●●●●●● ●●●●● ●●●●●●
Spyre Therapeutics presented clinical and preclinical data for its three IBD antibody candidates at the United European Gastroenterology Week 2026. The company showcased initial efficacy results for both monotherapy and combination approaches, though further clinical validation is required.…more
$90.33+0.08%vs prev close - 10.6Overnight26.10.06 15:36
●●●●●●●● ●●●●● ●●●●●●
Spyre Therapeutics has priced its public offering of common stock at $85.00 per share to raise $350 million. The company plans to use the proceeds to fund its gastroenterology, rheumatology, and dermatology development programs.…more
$90.33+0.08%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report